GSK
GSK to Acquire IDRx in $1.15B Deal
GSK will gain IDRx's lead candidate, the KIT inhibitor IDRX-42, an investigational treatment for KIT-mutant gastrointestinal stromal tumors.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Ideaya, GSK Cleared to Begin Phase I Trial of Werner Helicase Inhibitor in MSI-High Tumors
The companies have plans to evaluate IDE275 as a monotherapy and combined with immunotherapy in MSI-high solid tumors.
UK Parkinson’s Single-Cell Research Project Kicks off With £4M From Gatsby Charitable Foundation
The three-year public-private research partnership has also garnered financial support from pharmaceutical companies GSK, Novartis, Roche, and UCB.
Project Africa GRADIENT aims to gather and analyze pharmacogenetic data specific to African populations with funding from Novartis and GlaxoSmithKline.